GlassScriptPhysician profile
Michael W Christa
NPI 1013908128
$8,782.77
in general payments reported to CMS, 2019-2025
36 companies · $983 in 2025
The $983 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $990 · 2021: $1,187 · 2022: $1,332 · 2023: $1,304 · 2024: $1,300 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,581.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,132.43 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $714.27 | 2019-2025 | Jardiance |
| Abbvie INC. | $659.02 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $602.00 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $538.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $412.73 | 2019-2025 | |
| Astellas Pharma US INC | $389.43 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $371.40 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $331.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $270.26 | 2019-2023 | Dificid |
| Dexcom, INC. | $247.46 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $241.67 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $179.81 | 2021-2025 | |
| Pfizer INC. | $171.35 | 2019-2023 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Christa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.